The University of Chicago Header Logo

Connection

Michael Becker to Male

This is a "connection" page, showing publications Michael Becker has written about Male.
Connection Strength

0.626
  1. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
    View in: PubMed
    Score: 0.029
  2. Myocardial deformation by strain echocardiography identifies patients with acute coronary syndrome and non-diagnostic ECG presenting in a chest pain unit: a prospective study of diagnostic accuracy. Clin Res Cardiol. 2016 Mar; 105(3):248-56.
    View in: PubMed
    Score: 0.026
  3. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
    View in: PubMed
    Score: 0.026
  4. Urate transporters: transforming the face of hyperuricemia and gout. J Rheumatol. 2014 Oct; 41(10):1910-2.
    View in: PubMed
    Score: 0.024
  5. The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leuk Res. 2013 Sep; 37(9):1052-6.
    View in: PubMed
    Score: 0.022
  6. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
    View in: PubMed
    Score: 0.022
  7. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.021
  8. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
    View in: PubMed
    Score: 0.020
  9. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
    View in: PubMed
    Score: 0.019
  10. What do I need to know about gout? J Fam Pract. 2010 Jun; 59(6 Suppl):S1-8.
    View in: PubMed
    Score: 0.018
  11. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
    View in: PubMed
    Score: 0.018
  12. Trade-off in object versus spatial visualization abilities: restriction in the development of visual-processing resources. Psychon Bull Rev. 2010 Feb; 17(1):29-35.
    View in: PubMed
    Score: 0.018
  13. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May; 36(5):1041-8.
    View in: PubMed
    Score: 0.017
  14. Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transplant. 2008 Jul; 27(7):746-52.
    View in: PubMed
    Score: 0.016
  15. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
    View in: PubMed
    Score: 0.013
  16. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
    View in: PubMed
    Score: 0.013
  17. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1111-6.
    View in: PubMed
    Score: 0.012
  18. Sex on the internet: furthering our understanding of men with online sexual problems. Psychol Addict Behav. 2004 Sep; 18(3):223-30.
    View in: PubMed
    Score: 0.012
  19. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
    View in: PubMed
    Score: 0.012
  20. Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. Kidney Blood Press Res. 2019; 44(4):690-703.
    View in: PubMed
    Score: 0.009
  21. Electronic Health Record Mortality Prediction Model for Targeted Palliative Care Among Hospitalized Medical Patients: a Pilot Quasi-experimental Study. J Gen Intern Med. 2019 09; 34(9):1841-1847.
    View in: PubMed
    Score: 0.009
  22. Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem. 1999 Mar 12; 274(11):7482-8.
    View in: PubMed
    Score: 0.008
  23. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
    View in: PubMed
    Score: 0.008
  24. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
    View in: PubMed
    Score: 0.008
  25. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
    View in: PubMed
    Score: 0.008
  26. Use of two-dimensional speckle tracking echocardiography to predict cardiac events: Comparison of patients with acute myocardial infarction and chronic coronary artery disease. Clin Cardiol. 2018 Jan; 41(1):111-118.
    View in: PubMed
    Score: 0.008
  27. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018 04; 77(4):563-570.
    View in: PubMed
    Score: 0.008
  28. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
    View in: PubMed
    Score: 0.007
  29. Overexpression of the normal phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity of human phosphoribosylpyrophosphate synthetase. J Biol Chem. 1996 Aug 16; 271(33):19894-9.
    View in: PubMed
    Score: 0.007
  30. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
    View in: PubMed
    Score: 0.007
  31. Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):372-378.
    View in: PubMed
    Score: 0.007
  32. The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest. 1995 Nov; 96(5):2133-41.
    View in: PubMed
    Score: 0.007
  33. Current Orthopaedic Surgeon Practices for Nonarthroplasty Treatment of Osteoarthritis of Adult Hip and Knee. J Surg Orthop Adv. 2015; 24(4):213-20.
    View in: PubMed
    Score: 0.006
  34. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
    View in: PubMed
    Score: 0.006
  35. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
    View in: PubMed
    Score: 0.006
  36. Flow-synchronized ventilation of preterm infants with respiratory distress syndrome. J Perinatol. 1994 Mar-Apr; 14(2):90-4.
    View in: PubMed
    Score: 0.006
  37. A simplified method for the determination of phosphoribosylpyrophosphate synthetase activity in hemolysates. Clin Chim Acta. 1994 Jan 14; 224(1):55-63.
    View in: PubMed
    Score: 0.006
  38. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1745-52.
    View in: PubMed
    Score: 0.006
  39. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.006
  40. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7.
    View in: PubMed
    Score: 0.006
  41. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012 May; 71(5):614-23.
    View in: PubMed
    Score: 0.005
  42. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
    View in: PubMed
    Score: 0.005
  43. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
    View in: PubMed
    Score: 0.005
  44. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
    View in: PubMed
    Score: 0.005
  45. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
    View in: PubMed
    Score: 0.005
  46. Registration of coronary venous anatomy to the site of the latest mechanical contraction. Acta Cardiol. 2010 Apr; 65(2):161-70.
    View in: PubMed
    Score: 0.004
  47. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
    View in: PubMed
    Score: 0.004
  48. Neurodevelopmental impairment and deranged PRPP and purine nucleotide synthesis in inherited superactivity of PRPP synthetase. Adv Exp Med Biol. 1989; 253A:15-22.
    View in: PubMed
    Score: 0.004
  49. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
    View in: PubMed
    Score: 0.004
  50. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
    View in: PubMed
    Score: 0.004
  51. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
    View in: PubMed
    Score: 0.004
  52. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988 Sep; 85(3):383-90.
    View in: PubMed
    Score: 0.004
  53. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am. 1988 Aug; 14(2):377-94.
    View in: PubMed
    Score: 0.004
  54. The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol. 2008 Aug; 20(8):726-31.
    View in: PubMed
    Score: 0.004
  55. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
    View in: PubMed
    Score: 0.004
  56. Mechanisms of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetases. J Biol Chem. 1987 Apr 25; 262(12):5596-602.
    View in: PubMed
    Score: 0.004
  57. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006 Apr; 60(4):408-14.
    View in: PubMed
    Score: 0.003
  58. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol. 2005 Dec; 32(12):2368-72.
    View in: PubMed
    Score: 0.003
  59. Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines. J Clin Invest. 1985 Oct; 76(4):1657-64.
    View in: PubMed
    Score: 0.003
  60. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.003
  61. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004 Sep 18-24; 364(9439):1054-61.
    View in: PubMed
    Score: 0.003
  62. Human phosphoribosylpyrophosphate synthetase: radioimmunochemical quantitation in erythrocytes and fibroblasts. J Lab Clin Med. 1984 Jul; 104(1):96-109.
    View in: PubMed
    Score: 0.003
  63. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.003
  64. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology. 2002 Oct; 123(4):1020-5.
    View in: PubMed
    Score: 0.003
  65. Relationship of neonatal endotracheal tube size and airway resistance. Respir Care. 2002 Sep; 47(9):994-7.
    View in: PubMed
    Score: 0.003
  66. Mutations of the serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic pancreatitis. Am J Gastroenterol. 2002 May; 97(5):1133-7.
    View in: PubMed
    Score: 0.003
  67. Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr; 99(4):495-511.
    View in: PubMed
    Score: 0.003
  68. Superactive phosphoribosylpyrophosphate synthetase with altered regulatory and catalytic properties. Adv Exp Med Biol. 1980; 122A:387-92.
    View in: PubMed
    Score: 0.002
  69. Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J Clin Invest. 1980 Jan; 65(1):109-20.
    View in: PubMed
    Score: 0.002
  70. Comparison of two methods of surfactant administration and the effect on dosing-associated hypoxemia. J Perinatol. 1997 Nov-Dec; 17(6):450-4.
    View in: PubMed
    Score: 0.002
  71. Hip involvement in ankylosing spondylitis. Arthritis Rheum. 1976 Jul-Aug; 19(4):683-92.
    View in: PubMed
    Score: 0.002
  72. Recent advances in the identification of enzyme abnormalities underlying excessive purine synthesis in man. Arthritis Rheum. 1975 Nov-Dec; 18(6 Suppl):687-94.
    View in: PubMed
    Score: 0.002
  73. Human phosphoribosylpyrophosphate synthetase. Comparison of purified normal and mutant enzymes. J Biol Chem. 1975 Sep 10; 250(17):6822-30.
    View in: PubMed
    Score: 0.002
  74. Ventilatory management casebook. Bronchopulmonary dysplasias. Response to pressure support ventilation. J Perinatol. 1994 Nov-Dec; 14(6):495-7.
    View in: PubMed
    Score: 0.002
  75. Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
    View in: PubMed
    Score: 0.001
  76. Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16; 179(4078):1123-6.
    View in: PubMed
    Score: 0.001
  77. Ventilatory management casebook. Neonatal respiratory failure: response to volume ventilation. J Perinatol. 1993 Jan-Feb; 13(1):72-5.
    View in: PubMed
    Score: 0.001
  78. Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout. Adv Exp Med Biol. 1973; 41:307-15.
    View in: PubMed
    Score: 0.001
  79. Increased purine nucleotide degradation in the central nervous system (CNS) in PRPP synthetase superactivity. Adv Exp Med Biol. 1989; 253A:9-13.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.